Aprea Therapeutics (NASDAQ:APRE) Earns Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE – Free Report) in a research report report published on Monday morning, Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. Separately, Wedbush reiterated an outperform rating and set a $11.00 price target on shares of Aprea Therapeutics in […]
More Stories
Netflix’s Upcoming Adult Animated Series, Dang! Release Date, Trailer, Plot, and More
Are you ready to meet the most chaotic siblings on Netflix? The upcoming adult animated series, Dang!, is coming soon....
US Business Activity Hits 52-Month High in August: S&P Global
By Andrew Moran Business activity kicked into high gear this month, accelerating at its fastest pace in more than four...
US Imposes Sanctions on Hezbollah Cash Smuggling Ring
By Timothy Frudd The Treasury Department announced sanctions on Aug. 20 against 10 individuals accused of running a cash smuggling...
900 Visas Revoked in Birth Tourism Crackdown: State Department
By Jack Phillips The U.S. Department of State on Aug. 20 said that nearly 900 visas have been revoked since...
A Man on the Inside: Release Date, Trailer, Plot, and Episode Updates
Is your favourite detective, Ted Danson, returning with a season 3 of A Man on the Inside? Fans are looking...
8 Killed After Charter Plane Crashes in Western Alaska: US Military
By AldgraFredly The U.S. military said on Aug. 20 that eight people were killed after a charter plane crashed at...